Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

920
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
920
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K
Glaucoma: Overview01:25

Glaucoma: Overview

1.2K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rethinking Dry Eye and Ocular Surface Disesase in Glaucoma: Pathophysiology, Diagnosis, and Management.

Journal of glaucoma·2026
Same author

Rethinking Dry Eye and Ocular Surface Disease in Glaucoma: Pathophysiology, Diagnosis, and Management.

Journal of glaucoma·2026
Same author

Geographic Disparities in Access to Glaucoma Surgery: Lessons from a Nationwide Registry Study.

Journal of clinical medicine·2026
Same author

Intraocular Pressure During Short-Term Topical or Systemic Corticosteroid Treatment: Analysis of 3 Randomized Clinical Trials.

JAMA dermatology·2026
Same author

Optimizing topical glaucoma treatment outcomes: When less is better. A review on the clinical benefits of reducing treatment burden in glaucoma management.

European journal of ophthalmology·2026
Same author

Referral for glaucoma surgery and types of surgery in different European regions in 2025, the EURACCUR study.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026

Related Experiment Video

Updated: Jan 7, 2026

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.5K

Implants to Treat Glaucoma: Promising or Not?

Barbara Cvenkel1,2, Miriam Kolko3,4,5,6

  • 1Department of Ophthalmology, University Medical Centre Ljubljana, Grablovičeva 46, 1000, Ljubljana, Slovenia. barbara.cvenkel@mf.uni-lj.si.

Drugs & Aging
|December 31, 2025
PubMed
Summary
This summary is machine-generated.

Glaucoma treatment adherence is poor with eye drops. Sustained-release implants offer a promising solution to lower intraocular pressure (IOP) and improve patient quality of life.

More Related Videos

Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

12.6K
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.5K

Related Experiment Videos

Last Updated: Jan 7, 2026

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.5K
Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

12.6K
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.5K

Area of Science:

  • Ophthalmology
  • Drug Delivery Systems
  • Glaucoma Research

Background:

  • Glaucoma, a leading cause of blindness, involves progressive optic neuropathy and vision loss.
  • Elevated intraocular pressure (IOP) is the primary modifiable risk factor for glaucoma progression.
  • Current treatments like eye drops require lifelong adherence, which is often poor, leading to faster disease progression.

Purpose of the Study:

  • To review sustained-release systems for reducing intraocular pressure (IOP) in glaucoma management.
  • To address adherence barriers and enhance patient quality of life through innovative drug delivery.
  • To explore the potential of novel intraocular implants and neuroprotective strategies.

Main Methods:

  • Review of existing literature on sustained-release glaucoma treatment systems.
  • Analysis of approved and investigational intracameral implants.
  • Discussion of non-invasive drug-eluting delivery systems.

Main Results:

  • Non-invasive systems (contact lenses, punctal plugs) are not yet market-ready.
  • Two FDA-approved intracameral implants exist, with safety concerns limiting single use.
  • Biodegradable implants offer 4-6 months of drug release, while non-biodegradable ones last 36 months.

Conclusions:

  • Sustained-release implants show potential for improving glaucoma management and patient adherence.
  • Further research is needed on the long-term safety and efficacy of intracameral implants.
  • Future strategies may include neuroprotective implants and combination therapies for comprehensive glaucoma care.